Qiagen NV Share Price Nasdaq
Stocks
NL0000240000
Biotechnology & Medical Research
| Market Cap | 9.54B 8.48B 7.86B 7.15B 13.49B 905B 13.71B 94.48B 37.04B 472B 35.8B 35.04B 1,506B | P/E 2026 * |
24.1x | P/E 2027 * | 20.9x |
|---|---|---|---|---|---|
| Enterprise Value | 10.21B 9.07B 8.41B 7.65B 14.44B 969B 14.67B 101B 39.63B 505B 38.3B 37.49B 1,611B | EV / Sales 2026 * |
4.78x | EV / Sales 2027 * | 4.39x |
| Free-Float |
99.37% | Yield 2026 * |
0.29% | Yield 2027 * | 0.4% |
Last Transcript: Qiagen NV
| 1 day | -2.28% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jonathan Pratt
CEO | Chief Executive Officer | 56 | 31/08/2026 |
Roland Sackers
DFI | Director of Finance/CFO | 58 | 31/12/2003 |
Antonio Santos
COO | Chief Operating Officer | - | 31/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 31/05/2011 | |
Toralf Haag
BRD | Director/Board Member | 60 | 07/01/2021 |
Eva Pisa
BRD | Director/Board Member | 72 | 22/06/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.28% | -4.05% | - | - | 9.54B | |
| -6.60% | -8.56% | +42.79% | +64.16% | 65B | |
| -4.09% | -0.11% | +2.31% | +54.81% | 51.19B | |
| +0.03% | +5.56% | +10.18% | +41.75% | 51.2B | |
| -1.53% | +2.70% | +29.72% | +34.13% | 43.93B | |
| -1.34% | +4.12% | +16.05% | +112.18% | 41.96B | |
| -5.97% | -6.22% | +258.21% | +421.57% | 38.14B | |
| +6.53% | +8.02% | +15.74% | +53.94% | 33.24B | |
| -0.90% | -10.49% | +31.48% | -1.63% | 25.2B | |
| -2.76% | -9.54% | -16.53% | -9.55% | 22.03B | |
| Average | -1.89% | -1.67% | +43.33% | +85.71% | 41.32B | |
| Weighted average by Cap. | -2.30% | -1.21% | +43.56% | +88.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.14B 1.9B 1.76B 1.6B 3.02B 203B 3.07B 21.14B 8.29B 106B 8.01B 7.84B 337B | 2.24B 1.99B 1.85B 1.68B 3.17B 213B 3.22B 22.21B 8.71B 111B 8.42B 8.24B 354B |
| Net income | 418M 372M 345M 313M 591M 39.69B 601M 4.14B 1.62B 20.71B 1.57B 1.54B 66.02B | 483M 430M 398M 362M 683M 45.86B 694M 4.79B 1.88B 23.93B 1.81B 1.77B 76.29B |
| Net Debt | 666M 592M 549M 499M 942M 63.22B 957M 6.6B 2.59B 32.99B 2.5B 2.45B 105B | 309M 274M 254M 231M 437M 29.29B 444M 3.06B 1.2B 15.28B 1.16B 1.13B 48.72B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
